4DMedical’s FDA-cleared CT:VQ provides ventilation and perfusion insights from CT imaging.
RT’s Three Key Takeaways:
- Rapid Clinical Adoption: 4DMedical’s FDA-cleared CT:VQ software has been quickly adopted by leading U.S. medical centers, reflecting strong demand for advanced functional lung imaging.
- Major Investment Boost: The company secured over US$100 million in new funding to accelerate U.S. expansion, strengthen operations, and scale deployment of its CT-based ventilation and perfusion technology.
- Strategic Growth Focus: The funding will support wider commercial rollout, enhanced training and integration, continued R&D, and long-term partnerships to establish leadership in software-based lung imaging.
4DMedical has received US $100+ million (AU $150 million) in new funding to accelerate US adoption of its class-leading CT:VQ software-based lung imaging.
CT:VQ is 4DMedical’s FDA-cleared, SaaS technology that provides ventilation and perfusion insights from CT imaging. Within just four months of FDA clearance, CT:VQ was deployed by four elite US academic medical centers: Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health. These rapid adoptions reflect growing interest from clinicians seeking quantified, actionable and functional information not available from traditional imaging–but increasingly vital to support diagnosis, treatment planning, and longitudinal monitoring.
“This is an extraordinarily important and validating event for multiple reasons,” says Andreas Fouras, PhD, 4DMedical Founder and CEO. “First, it reflects growing global recognition of the technological leadership of 4DMedical, including our groundbreaking products such as CT:VQ. And it recognizes both the commercial progress and even greater growth potential we have in the US. With this strong institutional backing and a strengthened balance sheet, we will scale adoption, accelerate R&D, deepen partnerships, and dominate the global marketplace for software-based lung imaging tools.”
4DMedical will use the funding to expand U.S. availability of CT:VQ and support health systems with implementation at scale, including:
- Commercial expansion across US academic medical centers and health systems, with a focus on real-world adoption and multidisciplinary use
- Customer success, training, and technical support to help integrate CT:VQ into existing clinical workflows and drive consistent utilization
- Ongoing research and development to expand 4DMedical’s technology leadership, product portfolio and capabilities in functional lung imaging
- Operational scale and flexibility to support additional growth opportunities and sustained clinical partnerships
Following the raise, 4DMedical reported a pro forma cash position exceeding US $130+ million (AU $200+ million), which will support the company’s US expansion strategy and growing installed base.
link
About the Author
